• Sustainability
  • DE&I
  • Pandemic
  • Finance
  • Legal
  • Technology
  • Regulatory
  • Global
  • Pricing
  • Strategy
  • R&D/Clinical Trials
  • Opinion
  • Executive Roundtable
  • Sales & Marketing
  • Executive Profiles
  • Leadership
  • Market Access
  • Patient Engagement
  • Supply Chain
  • Industry Trends

Industry "Forming Response Plan" to Pricing Criticisms from Hillary et al


October 26, 2015.

Following high-profile drug-price criticisms from Hillary Clinton and others, Fortune last week reported Biogen's George Scangos and Lilly's John Lechleiter comments that the industry "is quietly formulating its response plan".   Scangos said the industry "is preparing a thoughtful presentation of a different perspective on drug prices and the value that we bring to patients and the medical community," while Lilly commented: “You can expect to see more coming from the industry."   Lechleiter explained: “We have a great story to tell. If you look at the hepatitis space, the cancer space, diabetes-there are huge advances in recent years…I’ve never been as optimistic about our chance to make a difference.” He said that the media focuses on drug price hikes has overlooked the fact that expense of drugs as a proportion of healthcare spending has remained “remarkably constant” over the years.   Scangos noted that "[if] we bring forward innovative drugs that make a difference in the lives of patients, they’ll continue to get attractive pricing."   http://fortune.com/2015/10/22/big-pharma-wont-stay-silent-in-drug-pricing-debate-for-long/  

Recent Videos
Related Content